Maxim’s healthcare analyst Jason Kolbert came out today with his views on IsoRay, Inc (NYSEMKT:ISR), after the company released its financial results for the quarter ended June …
In a research report released Wednesday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) with an $8 price …
In a research report released Tuesday, Maxim analyst Jason Kolbert maintained a Buy rating on shares of OncoSec Medical Inc (NASDAQ:ONCS) with a $17.00 …
In a research report issued Monday, Maxim Group analyst Jason McCarthy reiterated a Buy rating on shares of Kite Pharma Inc (NASDAQ:KITE) with a price …
In a research report released Monday, Maxim Group analyst Jason Kolbert maintained a Buy rating on shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) with an …
Omeros Corporation (NASDAQ:OMER) shot up more than 60% in pre-market trading on Tuesday after the pharmaceutical company announced additional positive data for OMS721 …
Maxim’s healthcare analyst Jason McCarthy weighed in with some commentary on Juno Therapeutics Inc (NASDAQ:JUNO), after the company announced that FDA has cleared its investigational new drug application for …
Maxim Group analyst Jason Kolbert came out today with a research report on Gilead Sciences, Inc. (NASDAQ:GILD), reiterating a Buy rating and a price target …
Maxim Group analyst Jason Kolbert was out pounding the table on TrovaGene Inc (NASDAQ:TROV) Thursday, reiterating a Buy rating and price target of $13, …
Maxim Group’s healthcare analyst Jason Kolbert came out with a research report on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) following the news that the company has reached its …
